Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update

• Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities • Appointed Rachel Humphrey, M.D., a... | August 15, 2022

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Jay Feingold ,Legochem Biosciences ,Courtney Dugan ,Rachel Humphrey ,Klara Sullivan ,Head Of Investor Relations Corporate Communications ,Corporate Development ,Clinical Development At Bristol Myers Squibb ,Pyxis Oncology Inc ,Company Quarterly Report On Form ,Globenewswire Inc ,Nasdaq ,Chief Executive Officer ,Drug Conjugate ,Investigational New Drug ,Chief Medical Officer ,Black Diamond Therapeutics ,Cytomx Therapeutics ,Vice President ,Clinical Development ,Bristol Myers Squibb ,Quarter Ended ,Common Stock ,Private Securities Litigation Reform Act ,Quarterly Report ,Oncology Contact ,Investor Relations ,Corporate Communications ,Consolidated Statements ,Pyxis Oncology ,Nc Stock Exchange ,News ,Information ,Press Release ,Prioritized ,Pipeline ,O ,Focus ,N ,Most ,Dvanced ,Programs ,Chile ,Maintaining ,Financial ,Flexibility ,Ursue ,Business ,Development ,Opportunities ,Appointed ,Achel Pyxs Us7473241013 ,